# Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia

> **NCT00503776** · PHASE2 · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 41 (actual)

## Conditions studied

- Dysphagia
- Head and Neck Cancer
- Mucositis
- Xerostomia

## Interventions

- **BEHAVIORAL:** exercise intervention
- **DRUG:** amifostine trihydrate
- **PROCEDURE:** therapeutic dietary intervention

## Key facts

- **NCT ID:** NCT00503776
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-01
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** funding became unavailable
- **Last updated:** 2017-06-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00503776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00503776, "Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00503776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*